There are currently 178 clinical trials in Overland Park, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including Menorah Medical Center, University of Kansas Cancer Center-Overland Park, Saint Luke's South Hospital and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Left Atrial Appendage Closure With WATCHMAN FLX Device in Recurrent Gastrointestinal Bleeding: The GI-FLX Registry
NCT06052358
Recruiting
The GI-FLX Registry is intended to create a registry of patients with a history of Atrial Fibrillation (AF) and Gastrointestinal (GI) bleed who will receive Left Atrial Appendage Closure (LAAC) with WATCHMAN FLX device and compare to patients with AF and GI bleed who do not have LAAC. The GI-FLX Registry will be a multi-center, non-randomized registry. Approximately 250 prospective patients will be enrolled at all 4 sites. Historical cohort of 250 patients after propensity score matching with WA... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2024
Locations: Kansas City Heart Rhythm Institute - Roe Clinic, Overland Park, Kansas +1 locations
Conditions: Atrial Fibrillation, GI Bleeding
Register for Updates
Use of 4D-ICE in Conjunction With TEE for Left Atrial Appendage Closure
NCT06061757
Recruiting
This is a prospective, single center, non-randomized study with two parallel arms intended to study if 4D Intracardiac echocardiography (4D-ICE) (Nuvision, Nuvera TM) will provide better visualization of the anatomical landmarks from the larger imaging volume and provide optimal intra procedural guidance similar to Transesophageal echocardiography (TEE) (GE 6VT-D ULTRASOUND TRANSDUCER) for Left atrial appendage closure (LAAC). The study will enroll approximately 52 subjects and will be followed... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/14/2024
Locations: Kansas City Heart Rhythm Institute - Roe Clinic, Overland Park, Kansas
Conditions: Atrial Fibrillation, Stroke
Register for Updates
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981
Recruiting
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of Kansas, Overland Park, Kansas
Conditions: Giant Cell Tumor of Bone
Register for Updates
HER2-positive Breast Cancer Registry
NCT06603597
Recruiting
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: KUCC - Indian Creek, Overland Park, Kansas +1 locations
Conditions: HER2 + Breast Cancer
Register for Updates
ENCALM: a Study of ENX-102 As a Monotherapy Treatment in Patients with Generalized Anxiety Disorder
NCT05749055
Recruiting
The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/29/2024
Locations: Collective Medical Research, Overland Park, Kansas
Conditions: Generalized Anxiety Disorder
Register for Updates
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
NCT05645380
Recruiting
This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
08/23/2024
Locations: The University of Kansas Cancer Center - Overland Park, Overland Park, Kansas
Conditions: Triple Negative Breast Cancer, Breast Cancer
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: University of Kansas Cancer Center-Overland Park, Overland Park, Kansas
Conditions: Multiple Myeloma
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: University of Kansas Cancer Center-Overland Park, Overland Park, Kansas
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Menorah Medical Center, Overland Park, Kansas +2 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Registry Study for Radiation Therapy Outcomes
NCT01255748
Recruiting
The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2024
Locations: Kansas City Proton Institute, Overland Park, Kansas
Conditions: Neoplasms
Register for Updates
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
NCT05521022
Recruiting
This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Midwest Heart and Vascular, Overland Park, Kansas
Conditions: Amyloidosis; Systemic
Register for Updates
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
NCT05143424
Recruiting
The purpose of this study is to analyze drug-drug interactions of CBD on co-administered Morphine as first step in understanding CBD-opioid interactions.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/25/2024
Locations: AltaSciences, Overland Park, Kansas
Conditions: Opioid Use Disorder
Register for Updates